Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2020, Vol. 31 ›› Issue (10): 104 doi: 10.1007/s41365-020-00809-3

• NUCLEAR CHEMISTRY,RADIOCHEMISTRY,RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE • Previous Articles     Next Articles

Radiolabeling of lacosamide using highly purified rhenium-188 as a prospective brain theranostic agent

H. A. El-Sabagh1 • M. I. Aydia2 • A. M. Amin1 • K. M. El-Azony2   

  1. 1Labeled Compound Department, Radioisotopes Production Division, Hot Laboratory Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt
    2 Radioactive Isotopes and Generators Department, Radioisotopes Production Division, Hot Laboratory Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt
  • Received:2020-04-14 Revised:2020-08-11 Accepted:2020-08-20
  • Contact: K. M. El-Azony E-mail: mmenaa_2004@yahoo.com
PDF ShareIt Export Citation
H.A. El-Sabagh, M.I. Aydia, A.M. Amin, K.M. El-Azony. Radiolabeling of lacosamide using highly purified rhenium-188 as a prospective brain theranostic agent.Nuclear Science and Techniques, 2020, 31(10): 104     doi: 10.1007/s41365-020-00809-3
Citations
Altmetrics

Abstract: Rhenium-188 is prospectively effective for both diagnosis and radiotherapy as it appropriately emits gamma rays and beta particles. Lacosamide (LCM) is a newly approved anti-epileptic medication for focal drug-resistant epilepsy. Rhenium-188 was separated with high elution yield and high purity using the new 188W/188Re generator based on the ZrSiW gel matrix. 188Re-LCM was prepared with high radiochemical yield and high purity. Biodistribution of 188Re-LCM in normal Swiss albino mice was investigated to determine its utility as a potential brain therapy agent. The 188W/188Re generator was used to obtain 188Re based on the ZrSi188W gel matrix, and the chemical, radiochemical, and radionuclidic purity of the obtained 188Re was determined using inductively coupled plasma optical emission spectrometry (ICP-AES), a paper chromatography technique, and high-purity germanium (HPGe) detection, respectively, to assess its validity for LCM labeling. Various factors, such as the pH, reaction time, and LCM quantity, were therefore studied in order to improve the yield and purity of 188Re-LCM, as determined by various chromatographic techniques such as electrophoresis, thin layer chromatography (TLC), and high-pressure liquid chromatography (HPLC). 188Re was obtained with a high elution yield (75±3%) and a low 188W breakthrough (0.001±0.0001%). The maximum radiochemical yield of 188Re-LCM (87.5±1.8%) was obtained using 50 μl LCM (4 mM), 250 μl stannous chloride (4.4 mM) at pH 4, 100 μl 188Re (37 MBq), within 30 min, at room temperature (25±3 °C), as determined by TLC, electrophoresis, and HPLC techniques. Biodistribution analysis showed that 188Re-LCM was primarily localized in the brain (5.1%) with a long residence time (240 min).

Key words: Lacosamide, 188Re, 188W/188Re generator, Radiolabeling

CLC Number: 


  • Cite this article

    H.A. El-Sabagh, M.I. Aydia, A.M. Amin, K.M. El-Azony. Radiolabeling of lacosamide using highly purified rhenium-188 as a prospective brain theranostic agent[J].Nuclear Science and Techniques, 2020, 31(10): 104-104.

-->